Format

Send to

Choose Destination
Clin Calcium. 2015 Nov;25(11):1645-51. doi: CliCa151116451651.

[Hepatocellular carcinoma and vitamin K2].

[Article in Japanese]

Author information

1
Internal Medicine, Imari-Arita Kyoritsu Hospital, Japan.
2
Health Administration Center, Saga University, Japan.

Abstract

Despite recent progress in diagnosis and therapy, hepatocellular carcinoma(HCC)remains among the cancers with the poorest prognoses. Vitamin Ks(VKs)have been shown to suppress the growth of HCC cells. Long-term administration of VK2 has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK2 against HCC, co-administration of VK2 with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.

PMID:
26503869
DOI:
CliCa151116451651
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center